Literature DB >> 29620053

Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Rachel J Harding1, Yu-Feng Tong1,2.   

Abstract

Many neurodegenerative diseases are characterized by impairment of protein quality control mechanisms in neuronal cells. Ineffective clearance of misfolded proteins by the proteasome, autophagy pathways and exocytosis leads to accumulation of toxic protein oligomers and aggregates in neurons. Toxic protein species affect various cellular functions resulting in the development of a spectrum of different neurodegenerative proteinopathies, including Huntington's disease (HD). Playing an integral role in proteostasis, dysfunction of the ubiquitylation system in HD is progressive and multi-faceted with numerous biochemical pathways affected, in particular, the ubiquitin-proteasome system and autophagy routes for protein aggregate degradation. Unravelling the molecular mechanisms involved in HD pathogenesis of proteostasis provides new insight in disease progression in HD as well as possible therapeutic avenues. Recent developments of potential therapeutics are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620053      PMCID: PMC5943907          DOI: 10.1038/aps.2018.11

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  174 in total

Review 1.  Is target validation all we need?

Authors:  Melanie M Frigault; J Carl Barrett
Journal:  Curr Opin Pharmacol       Date:  2014-09-27       Impact factor: 5.547

2.  Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.

Authors:  A Sittler; R Lurz; G Lueder; J Priller; H Lehrach; M K Hayer-Hartl; F U Hartl; E E Wanker
Journal:  Hum Mol Genet       Date:  2001-06-01       Impact factor: 6.150

3.  Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats.

Authors:  Tamara Ratovitski; Robert N O'Meally; Mali Jiang; Raghothama Chaerkady; Ekaterine Chighladze; Jacqueline C Stewart; Xiaofang Wang; Nicolas Arbez; Elaine Roby; Athanasios Alexandris; Wenzhen Duan; Ravi Vijayvargia; Ihn Sik Seong; Daniel J Lavery; Robert N Cole; Christopher A Ross
Journal:  J Proteome Res       Date:  2017-07-03       Impact factor: 4.466

4.  Sulforaphane Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity by Activating the Keap1-Nrf2-ARE Pathway and Inhibiting the MAPKs and NF-κB Pathways.

Authors:  Minhee Jang; Ik-Hyun Cho
Journal:  Mol Neurobiol       Date:  2015-06-23       Impact factor: 5.590

5.  Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.

Authors:  N R Jana; M Tanaka; G h Wang; N Nukina
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

6.  Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.

Authors:  John Labbadia; Helen Cunliffe; Andreas Weiss; Elena Katsyuba; Kirupa Sathasivam; Tamara Seredenina; Ben Woodman; Saliha Moussaoui; Stefan Frentzel; Ruth Luthi-Carter; Paolo Paganetti; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

7.  Enhancement of proteasome activity by a small-molecule inhibitor of USP14.

Authors:  Byung-Hoon Lee; Min Jae Lee; Soyeon Park; Dong-Chan Oh; Suzanne Elsasser; Ping-Chung Chen; Carlos Gartner; Nevena Dimova; John Hanna; Steven P Gygi; Scott M Wilson; Randall W King; Daniel Finley
Journal:  Nature       Date:  2010-09-09       Impact factor: 49.962

8.  HSP90 recognizes the N-terminus of huntingtin involved in regulation of huntingtin aggregation by USP19.

Authors:  Wen-Tian He; Wei Xue; Yong-Guang Gao; Jun-Ye Hong; Hong-Wei Yue; Lei-Lei Jiang; Hong-Yu Hu
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

9.  A novel brain-enriched E3 ubiquitin ligase RNF182 is up regulated in the brains of Alzheimer's patients and targets ATP6V0C for degradation.

Authors:  Qing Yan Liu; Joy X Lei; Marianna Sikorska; Rugao Liu
Journal:  Mol Neurodegener       Date:  2008-02-25       Impact factor: 14.195

10.  Huntingtin functions as a scaffold for selective macroautophagy.

Authors:  Yan-Ning Rui; Zhen Xu; Bindi Patel; Zhihua Chen; Dongsheng Chen; Antonio Tito; Gabriela David; Yamin Sun; Erin F Stimming; Hugo J Bellen; Ana Maria Cuervo; Sheng Zhang
Journal:  Nat Cell Biol       Date:  2015-02-16       Impact factor: 28.824

View more
  22 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

2.  A new platform for international collaboration on pharmacology and drug development: 2017 China-Canada-USA Pharmacology/Physiology Conference.

Authors:  Zhong-Ping Feng; Hong-Shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2018-05       Impact factor: 6.150

Review 3.  The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention.

Authors:  Abdelmagid M Elmatboly; Ahmed M Sherif; Dalia A Deeb; Amira Benmelouka; May N Bin-Jumah; Lotfi Aleya; Mohamed M Abdel-Daim
Journal:  Environ Sci Pollut Res Int       Date:  2020-02-19       Impact factor: 4.223

4.  Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model.

Authors:  Zih-Ning Huang; Jie-Mao Chen; Liang-Ching Huang; Yi-Hsuan Fang; Lu-Shiun Her
Journal:  Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.590

Review 5.  Spermatozoan Metabolism as a Non-Traditional Model for the Study of Huntington's Disease.

Authors:  Meghan Lawlor; Michal Zigo; Karl Kerns; In Ki Cho; Charles A Easley Iv; Peter Sutovsky
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

6.  "Trim"ming PolyQ proteins with engineered PML.

Authors:  Neha Dhar; Ammar Arsiwala; Shruthi Murali; Ravi S Kane
Journal:  Biotechnol Bioeng       Date:  2019-11-28       Impact factor: 4.530

Review 7.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 8.  The proteasome and its role in the nervous system.

Authors:  Fulya Türker; Emily K Cook; Seth S Margolis
Journal:  Cell Chem Biol       Date:  2021-04-26       Impact factor: 9.039

Review 9.  Gene targeting techniques for Huntington's disease.

Authors:  Eric Fields; Erik Vaughan; Deepika Tripu; Isabelle Lim; Katherine Shrout; Jessica Conway; Nicole Salib; Yubin Lee; Akash Dhamsania; Michael Jacobsen; Ashley Woo; Huijing Xue; Kan Cao
Journal:  Ageing Res Rev       Date:  2021-06-05       Impact factor: 11.788

Review 10.  Biological Aging and the Cellular Pathogenesis of Huntington's Disease.

Authors:  Emily Machiela; Amber L Southwell
Journal:  J Huntingtons Dis       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.